These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39009522)

  • 21. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):287-297. PubMed ID: 30471054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generic script share and the price of brand-name drugs: the role of consumer choice.
    Rizzo JA; Zeckhauser R
    Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of an interchangeability switch in patients treated with clozapine: A retrospective review.
    Alessi-Severini S; Honcharik PL; Simpson KD; Eleff MK; Collins DM
    J Clin Psychiatry; 2006 Jul; 67(7):1047-54. PubMed ID: 16889447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ; Kamat S; Fang C
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Evaluation of Health Service Impacts Consequent to Switching from Brand to Generic Venlafaxine in New Zealand under Conditions of Price Neutrality.
    Lessing C; Ashton T; Davis P
    Value Health; 2015 Jul; 18(5):646-54. PubMed ID: 26297093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prediction of systemic exposure of ketoprofen tapes by in vitro release test and pharmacokinetic model analysis: comparison between brand-name and generic formulations].
    Awa K; Satoh H; Hori S; Sawada Y
    Yakugaku Zasshi; 2012; 132(1):135-44. PubMed ID: 22214588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of autoimmune hepatitis which worsened after switching from a brand name to a generic version of prednisolone].
    Kakizaki S; Suzuki H; Ichikawa T; Sato K; Takagi H; Mori M; Yuasa K
    Nihon Shokakibyo Gakkai Zasshi; 2009 Oct; 106(10):1488-93. PubMed ID: 19834296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.
    Hansen RA; Qian J; Berg R; Linneman J; Seoane-Vazquez E; Dutcher SK; Raofi S; Page CD; Peissig P
    Pharmacotherapy; 2017 Apr; 37(4):429-437. PubMed ID: 28152215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study.
    Corrao G; Soranna D; Merlino L; Mancia G
    Eur J Clin Invest; 2014 Oct; 44(10):933-9. PubMed ID: 25132063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.
    Margolese HC; Wolf Y; Desmarais JE; Beauclair L
    Int Clin Psychopharmacol; 2010 May; 25(3):180-2. PubMed ID: 20216221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medication persistence and the use of generic and brand-name blood pressure-lowering agents.
    Corrao G; Soranna D; La Vecchia C; Catapano A; Agabiti-Rosei E; Gensini G; Merlino L; Mancia G
    J Hypertens; 2014 May; 32(5):1146-53; discussion 1153. PubMed ID: 24569417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin.
    Sicras-Mainar A; Rejas-Gutiérrez J; Pérez-Paramo M; Sánchez-Alvarez L; Navarro-Artieda R; Darbà J
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):45-57. PubMed ID: 30182806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels.
    Brito JP; Ross JS; Sangaralingham L; Dutcher SK; Graham DJ; Wang Z; Wu Y; Yao X; Smallridge RC; Bernet V; Shah ND; Lipska KJ
    JAMA Netw Open; 2020 Sep; 3(9):e2017645. PubMed ID: 32997127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes].
    Izumi T; Hori S; Satoh H; Miki A; Sawada Y
    Yakugaku Zasshi; 2012; 132(5):617-27. PubMed ID: 22687698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B.
    Hsu PK; Su PY; Wu CL
    BMC Gastroenterol; 2022 May; 22(1):228. PubMed ID: 35538425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.